Clinical trials: Antipsychotic
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Bipolar I Disorder
Risperdal Consta for Bipolar Disorder
We recruited 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who were about to initiate or switch their current antipsychotic agent.
- Trial name
- NCT00177164
- Testing
- Injectable Risperidone (Consta) or oral antipsychotic
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Medication Administered in Error, Antipsychotics and Neuroleptics Toxicity
Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing
This pilot project aims to reduce the prescribing of high-risk medications, such as antipsychotics and benzodiazepines, to hospitalized older adults. To accomplish this, this project consists of two phases.
- Trial name
- NCT04668248
- Testing
- Simulation, Online educational training
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Metabolic Complications
Metformin for the Prevention of the Metabolic Side-effects of Zyprexa
We hypothesize that metformin co-administered with olanzapine will be well tolerated and associated with significantly less insulin resistance, weight gain and dyslipidemia as compared to olanzapine plus placebo.
- Trial name
- NCT00682448
- Testing
- Metformin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rush University Medical Center
Schizophrenia
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment.
- Trial name
- NCT03351244
- Testing
- BI 409306
- Where
- 59 sites in United States, Canada and 5 more
- Volunteers
- 264 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation…
- Trial name
- NCT02469155
- Testing
- ITI-007, Risperidone
- Where
- 11 sites in United States
- Volunteers
- 696 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Sialorrhea
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
- Trial name
- OPTIMYST (NCT02610868)
- Testing
- MYOBLOC
- Where
- 35 sites in United States, Belarus and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Schizophrenia
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients…
- Trial name
- NCT00183625
- Testing
- Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- University of California, Los Angeles
Autistic Disorder
Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.
- Trial name
- NCT00198107
- Testing
- Aripiprazole, D-cycloserine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Indiana University
Schizophrenia
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
- Trial name
- NCT00333177
- Testing
- Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Drug-induced Weight Gain
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
- Trial name
- NCT05857566
- Testing
- RDX-002 + Olanzipine, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Response Pharmaceuticals
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Autistic Disorder, Autism
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical…
- Trial name
- NCT00576732
- Testing
- Risperidone high dose, Risperidone low dose
- Where
- 20 sites in United States
- Volunteers
- 96 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.